Disease area
Hematologic malignancies
Multiple myeloma
B-cell malignancies
Myeloid malignancies
Classical hematology
Showing 5 recruiting clinical trials
Advanced solid tumors
87890387STM1001
Phase
NCT06178614
Compound
JNJ-87890387 (ENPP3 × CD3 bispecific Ab)
Advanced solid tumors
89862175LUC1001
Phase
NCT07223125
Compound
JNJ-89862175 (ENPP3 ADC)
Advanced solid tumors
95437446LUC1001
Phase
NCT07107230
Compound
JNJ-95437446 (EGFR × MET ADC)
Advanced solid tumors
1761981STM1001
Phase
NCT07525141
Compound
JNJ-1761981 ER (an extended-release chemotherapy)
Intratumoral study
Intratumoral study
ER+ MBC or locally advanced BC
HLD-0117-ONC-101
Phase
NCT07524855
Compound
JNJ-101684362*
The safety and efficacy of the investigational use of these products have not been determined.
There is no guarantee that the investigational uses listed will be filed with and/or approved for marketing by any regulatory agency.
Ab, antibody; ADC, antibody-drug conjugate; CD, cluster of differentiation; EGFR, epidermal growth factor receptor; ENPP3, ectonucleotide pyrophosphatase/phosphodiesterase 3; MET, mesenchymal epithelial transition factor.